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SYMPOSIUM PROCEEDINGS
Following the presentation of the papers by the symposium
participants, the speakers addressed questions posed by various
audience members. The inquires made and responses given are
printed below.
Audience Member (to Professor Turkington and Mr. Burris):
I have the impression that you view the federal government as the
sole source of a response to AIDS and that the federal courts and
Congress are the fonts of rationality. What about claims in the
state courts? Can't arguments based on state constitutions, which
often provide greater protection than does the United States
Constitution, or on state legislative alternatives that are being de-
veloped to cope with this crisis be made?
Professor Turkington: I hope that I did not leave the impres-
sion that I thought that the federal government was the fountain
of wisdom. You raise a very good question. There is a tendency
in the confidentiality area for state courts to take the lead in pro-
tecting rights and to be more sympathetic to constitutional pri-
vacy and informational privacy arguments than before. I think
this is because of the powerful arguments linking AIDS and pri-
vacy and the risks of disclosing AIDS-related information. The
Wisconsin case of Woods v. WhiteI goes beyond Supreme Court
precedent in holding that disclosure by the government of inti-
mate information might violate the constitutional right of privacy.
The Supreme Court case, Whalen v. Roe,2 merely suggests that
and is dicta. Poor legislation can to some extent be corrected by
the courts' finding it unconstitutional. Thus, the constitutional
developments do provide some check on policies that are wrong-
headed. However, I would not want to bring the question of
whether the disclosure of HIV- or AIDS-related information vio-
lated a person's constitutional right of informational privacy
before the current Supreme Court. I cannot see the Rehnquist
Court expanding constitutional informational privacy rights.
Nevertheless, as you point out, there are several state courts that
interpret their state constitutions in such a way as to give greater
informational privacy rights. These state courts would be quite
sympathetic to such a privacy argument given the right case. Ex-
1. 689 F. Supp. 874 (W.D. Wis. 1988).
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amples of such state courts include those of Pennsylvania, New
York, New Jersey and California and maybe a couple of others.
State constitutional development, at least in some states, may
provide a balance against wrong-headed legislation to protect in-
formational privacy rights.
Mr. Burris: I would like to comment to that a certain degree.
The Rehabilitation Act and the decisions surrounding it are a
fountain of rationality in that they encourage people to try and fit
their claims into the Act and decisions construing it. Speed is also
a factor. There is very limited time in which a person with AIDS
or HIV is interested or able to pursue litigation and federal courts
are swifter.
Ms. Dunlap: I would not say that either the federal or the
state governments should be expected to be a font of rationality.
The purpose of my presentation was to make the point that the
opposite has too often been the case. As for the California state
courts taking on questions of constitutional privacy, California's
constitution guarantees privacy on its face, interestingly enough,
by means of a voter initiative fifteen years ago that adopted a con-
stitutional amendment. I am not even a little bit sanguine about
the prospects of surviving this court's review. The California
Supreme Court was the subject of a right-wing attack which re-
sulted in the removal of Rose Bird and President George Bush
promises not to appoint anyone like Rose Bird to the federal
courts, so I guess we are gone.
Audience Member (to Ms. Dunlap): How have employers re-
acted to the fear of a Title VII suit versus fellow employee para-
noia? Have they just decided to fire the employees?
Ms. Dunlap: There have been a number of cases involving
employee terminations. The San Francisco Human Rights Com-
mission, for example, has documented some several hundred
cases where people believe they have been dismissed from their
employment because of AIDS, ARC, HIV infection or fear in a
first amendment sense because of their association with people
with AIDS. Employers vary dramatically in their policies. We
have models in San Francisco, such as Levi Strauss, which have
done a magnificent job nationally in educating employers about
the importance of not overreacting. At the other extreme, we
have employers who have openly fired people and taken their
chances. Very few of those cases make it to court because there
are problems of resources and of priorities. If I were in the last
years of my life, one of the last things I would choose to do would
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be to litigate. Keep in mind that when you are thinking about
people enforcing existing rights, extending rights to new contexts
or developing rights, many people with AIDS and ARC do not
find it a particularly desirable choice to fight these battles. Ques-
tions of doctrinal standing and the like get in the way of the devel-
opment of consistent principles. The employment cases are
generally optimistic, as I said, but with a caveat that this underly-
ing wave or current of irrationality-well, we called it irrationality,
but it may be something worse-may overwhelm any possible
optimism.
For that matter, I don't think reason is the total answer. The
Quilt is the answer. The Quilt is more than reason; it is connect-
edness; it is grassroots organizing; it is a whole variety of things.
Some employers have taken all that into account.
Audience Member (to Professor Annas): Assuming that
eventually there will be an effective vaccine or some kind of tech-
nological fix, what lasting changes or overall historical signifi-
cance do you see in the current response to the AIDS epidemic?
Professor Annas: First, just let me comment on the "techno-
logical fix." The NIH, C. Everett Koop and every other knowl-
edgeable scientist in the world do not expect a vaccine before the
year 2000 at the very earliest. Thus, we are looking way into the
future. Then, it would probably take another ten years to test
that vaccine. So, don't expect a vaccine. Treatment drugs?
Maybe, but Commissioner Young, who is the most energetic and
optimistic person, does not see more than one or two drugs that
are even a little bit better than AZT being available before the
year 1991. Of course, we hope that there is going to be some
technological fix, but it won't be soon.
Mr. Burris: As far as changes go, I think a lot of that depends
on our response to AIDS. It is very easy for society to continue to
discriminate. This is a society that has fundamental changes
every couple of years, and consequently I discount about ninety-
nine percent of the analysis I hear of our "great" social changes.
Nevertheless, you raised a point that is worth making. It depends
on who this disease hits. If AIDS remains the disease of gay peo-
ple and poor people and we as a society just let it happen and
become part of the impression about gay people and part of the
business as usual of the third world health conditions in the
ghetto, then AIDS won't change us for the better. It may tend to
make us more like oligarchists in Central America, detached from
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ment of the population. However, I do not see changes ahead in
the sense of people really saying, "Well, my sexual practices have
got to change." I do not see changes in the sense of people say-
ing, "This disease shows us how unfair this society is." But AIDS
does show us how unfair society is. It shows how many people are
deprived of the basic necessities of life. The problem is that AIDS
is not really doing enough.
Professor Furrow: There are a couple of historical examples
that are interesting. The history of tuberculosis in the United
States from 1900-1910 is one such example. New Mexico had
had on its books for a long time a statute that empowered a public
health officer to arrest someone who was suspected to be a T.B.
carrier. That statute goes back to the days before tuberculosis
could be treated. There is also a very nasty tradition in tort law
that dates back to that same period involving use of public nui-
sance law to keep sanitaria out of the suburbs. This is advanced
zoning as in Euclid.3 Tort law was used to do effectively what peo-
ple want to do today through zoning or through referenda to
keep suspect and contagious groups out of their community.
There is history and there is precedent that suggests that we have
been nasty in the past. However, this is worse.
Ms. Dunlap: Let me offer that Michael Callen, a person with
AIDS, AIDS activist and musician, has said: "AIDS is a cosmic
kick in the ass." I love that for its ability to describe some of the
ways in which AIDS magnifies both existing problems and areas
of change. Among the ones I note in my article are that: the legal
system is too often punitive rather than educational, decent medi-
cal care costs more money than most people have; the debate on
national health insurance certainly is being conducted in the light
of the proposition that AIDS affects and will continue to affect a
great number of people; the average cost of AIDS health care is
estimated at somewhere between just less than $30,000 up to
$120,000 per person over the life of the disease. This is a very
important area of change which once again the Quilt embodies;
the nation suffers from a massive denial of the realities of illness
and death.
In reference to Dr. Annas's remarks about the whales, 4 while
3. Village of Euclid v. Ambler Realty Co., 272 U.S. 365 (1926).
4. Dr. Annas began his presentation with the following remarks to which
Ms. Dunlap was responding.
The topic that I am going to address is "The Regulation of AIDS
Drugs," but it has a subtitle. This subtitle has developed over the last
year as I have been thinking about this topic and seen it as a moving
986 [Vol. 34: p. 983
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I don't necessarily agree with him, I would save the whales before
I would save the FDA. In fairness to Dr. Annas, AIDS is illumi-
nating the key point that we are in deep, tragic denial about the
nature of death itself and we look for technological fixes against
our own mortality.
Finally, my major point was that AIDS has the capacity to
teach those of us who work in the legal system to overcome our
own bigotry. It also has the capacity to enable us to embed that
bigotry even further in our values. AIDS has both potentials. I
don't mean to sound too Buddhist about this, but we see both
capacities in our reactions to this epidemic.
Professor Furrow: If I may make one magnifying point build-
ing on that metaphor. There was a recent study that ranked the
United States as compared to eleven other countries, European,
and Turkey and Greece, in terms of the proportion of our gross
national product we spend on health care generally and in terms
of the amount of our health care expenditures that we spend on
public health-defined health care. The United States ranks first,
or worst, on the proportion of money in GNP we spend on health
target. As you read in the New York Times and other papers almost daily
now, the FDA changes its rules. The subtitle of this presentation is
"Rescue Fantasy at the FDA." I will focus on how the AIDS epidemic
tests our notions of what is safe and effective in drugs and on what
regulatory agencies should do in response to this very difficult issue.
I want to begin with a drama that the whole world is watching
which is the three whales that are trapped beneath the ice cap in Alaska,
although I understand that this morning there are only two survivors.
It has been one of those rare dramas that has brought the world to-
gether in a sense of the electronic global village, to witness and to hope
and to try to help these trapped creatures. The question has to be
asked: Why? Why do we care about these three whales? There have
been a lot of suggestions about that in the last week, and it seems to me
the reasons are two. The primary reason is because we fear death and
we do not want to see creatures die because it reminds us of our mor-
tality. Secondly, we believe as a society, if not individually, that our
technology can avert death; that our technology is strong enough and
powerful enough to save creatures from death and therefore to save
ourselves from death. We see this as an affirmation of the ability of
technology to save ourselves and the whales from death, and that is why
we put our technology to the test in Alaska.
Whether it fails or not is not the point. The point is that we do this
for a purpose: to reinforce our belief in life and our belief in technol-
ogy as life preserving. I suggest to you that that is a rescue fantasy.
That is a fantasy for us to believe-that the whales can live forever, that
we can live forever. It is a fantasy for us to believe that our technology
can solve all of our problems. That is exactly the problem we confront
with the AIDS epidemic. We are confronted for the first time in mod-
ern history with an epidemic, a disease that we are powerless to deal
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care. That is, the U.S. spends the most, and that is compared to
Norway and Sweden, countries with socialized medicine. The
United States ranks last in the proportion of health care expendi-
tures we spend on public health, and that is compared to Turkey,
for example. Now it seems to me, that the AIDS epidemic may
magnify that particular kind of imbalance we have in the Ameri-
can political system.
Audience Member (to Professor Annas): Part of your argu-
ment for advocating a strong FDA and the preservation of experi-
mental and regulatory controls is a limit on the profusion of
quackery in AIDS treatments which is a variant of a "save the peo-
ple from themselves" argument. I wonder why you advocate this
approach in the area of AIDS drugs when, for instance, we do not
take that approach in many other areas; we allow people to use
carcinogenic tobacco products with little limitation. You men-
tioned that part of the reason for doing this was the utility of pre-
serving scientific soundness and a harmonization of AIDS drug
trials with other drug policies in this society. Isn't this essentially
a social utility argument?
Professor Annas: I advocate scientific soundness for all
drugs, not just AIDS drugs. The concern is that AIDS drugs will
drive all of the other drugs down to their level, rather than AIDS
drugs being the exception. That is what happens. That is what
the drug companies want. Essentially, the drug companies have
wanted two things for years. First, they want to be able to charge
money for experimental drugs, and they are doing that now with
the so-called treatment INDs, or investigational new drugs. Sec-
ond, they want Congress to pass a statute limiting their liability in
products liability drug suits. The drug companies do not have
that yet, but it is the next step considering the President's AIDS
Commission report. The report points out that the main reason
treatment INDs have not been used by drug companies is that
they are worried about their potential liability. The Commission
did not recommend to Congress that it pass such a statute, but
the drug companies will lobby for it.
Indeed, I would argue the same thing as C. Everett Koop rec-
ommended strongly in the New York Times on October 22, 1988,
and as many other health officials do, that the FDA designate the
new smokeless cigarette "Premier" as a drug or at least as a drug
device. Commissioner Young has said that he would like to do
that, but the only reason he might not be able to do so is because
all of his staff is currently working on AIDS. The FDA might just
988 [Vol. 34: p. 983
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be swamped with R.J. Reynolds trying to fight that. The FDA can-
not do its job for other drugs. The FDA cannot do its job to pro-
tect the public health. We have 300,000 people who die each year
of illnesses related to cigarettes.
I am not saying that AIDS is not a problem, but we have
other problems too. If we let AIDS drive out all other health and
drug problems, we have got major problems. If you listen care-
fully to what Mr. Burris said, I think he is absolutely right that the
United States Supreme Court is finally starting to listen to scien-
tific rationality and reasoning. That is what he wants the Court to
do, and so do I. Nevertheless, it is difficult to argue to the Court
that when we talk about prejudice and fear, it should listen to sci-
ence and be rational on the one hand, and on the other hand,
when I want my drugs, forget science and rationality. Just give
me what I want.
Audience Member (to Professor Turkington): For years and
years, workers in manufacturing industries have dogged their em-
ployers to find out what carcinogenic or toxic substances they
were being exposed to in the workplace. Manufacturers pro-
tected themselves by saying that they could not release that infor-
mation because to do so would force them to disclose trade
secrets and violate their property rights. But nonetheless, the
workers eventually got past the manufacturers' maneuvering with
the Right to Know Act. Can you draw a distinction between the
right of a chemical worker, for instance, to know what they are
being exposed to in the workplace with a spouse's right to know if
their husband or wife has AIDS?
Professor Turkington: That is a very good question. I cer-
tainly can draw a distinction between an employer's right to know
about HIV- or AIDS-related information in respect to employees
or fellow employees' right to know about HIV- or AIDS-related
information in respect to other employees and an employee's
right to know about conditions which in a meaningful way
threaten her life.
The question of informing the spouse, I think, is one of the
most difficult in the area of confidentiality. I have come around
reluctantly-although I may change my view-to the position that
the New York statutes which I summarized in my presentation are
probably a good accommodation of the interest in protecting the
spouse from the risk of infection and the interest in privacy and
protecting the integrity of the professional-client relationship. It
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medical profession, or at least some members of the medical pro-
fession, takes the view that the responsibility ought to lie primar-
ily with the health department to perform the police function.
Second, the law is very unclear as to what the duty is or whether
there is liability if you do disclose the information. If you do not
disclose, Tarasoffp is not controlling precedent in that there are
significant differences between the two situations. One difference
is that in the Tarasoff situation, the patient is in no position to
inform the endangered party of the problem, whereas with AIDS,
the patient may be the right person to inform and discuss with the
spouse or significant other the fact of infection.
It is a very difficult question, and the New York statute re-
flects a fair accommodation of the conflicting values. In circum-
stances as prescribed under the New York statutes, a physician
who chooses to disclose ought to be able to do so and should be
protected against civil liability. The question is whether the
health department has an obligation, as it does with other conta-
gious diseases, to try to locate past and present sexual partners
who might be at risk.
Audience Member (to Professor Annas): Given that the suc-
cess of a randomized double blind placebo trial is going to be
dependent on the willingness of participants to obey the guide-
lines of the trial, where would you put in a legal context those
trial participants who take their drugs to a pharmacist to have
them analyzed to determine whether they are in fact drug or pla-
cebo after which the participants make their decision about com-
pliance? Where would you put those doctors who conduct their
own small scale nonrandomized trials of alternative therapies,
and there are many of these being conducted in New York, San
Francisco and Los Angeles? Do you anticipate any legal sanctions
against either these patients or physicians?
Professor Annas: No, I don't. I do not think we will learn
anything from those studies unfortunately. Those patients may
be found out when we get bad data on the basis of the random-
ized clinical trials. Of the doctors who are doing the small scale
trials, most of them are performing the trials because there are no
other studies that those patients qualify for, and the patients re-
ally want to be in studies. I have nothing against that. That is fine
although, unless very careful data are taken, it is unlikely that any-
thing will be learned from them. You may learn something from
5. Tarasoff v. Regents of the University of California, 17 Cal. 3d 425, 551
P.2d 334, 131 Cal. Rptr. 14 (1976).
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these small studies. You are never going tolearn anything from
experiments individuals do on themselves by mail ordering drugs
from other countries and administering them to themselves. The
small studies have some possibility, but not much. The odds are
so great that you are not going to learn anything that way that it is
almost a waste of time. I am not saying it is totally a waste of
time.
Dr. Fauci has said, for example, that the NIH is going to be
testing 10,000 different compounds in 1989 andevery year from
now on-10,000 compounds a year in vitro, in the test tube, that it
has on the shelves against the AIDS virus. He does not expect to
find anything that works there, but, nonetheless, he is going to do
it. David Baltimore, from MIT, thinks we need a whole new ap-
proach; we need a whole new science of virology to do this. We
are much more likely to learn of a new approach, not by testing
things that are already out there, but by developing a new anti-
viral technique which will require some new insights. There are
eighteen working groups around the country trying to do that. It
is very frustrating for people. I am not arguing that it is not frus-
trating for people who have AIDS, cancer or other diseases.
What I am arguing is that, as cruel as it sounds, it is probably
better for these people to start coming to terms with their dis-
eases and their death, than it is for them to go running around for
what are basically quack remedies.
Audience Member (to Professor Annas): It sounds like you
are saying that you feel that these individuals should be involunta-
rily relegated to the status of the experimental control. In other
words, if they cannot have drugs of their own choosing, they are,
in effect, being the population controls for the natural history of
the disease, whether they want to be or not.
Professor Annas: No one can have drugs of their own choos-
ing. That is the question: Do we want to eliminate the drug laws
or not? I do not, but I can understand those who do. That is
absolutely the question. The real issue is not, as Judge John Mar-
shall tried to frame it in the Dallas Gay Alliance suit against Park-
land Memorial Hospital." Judge Marshall said: "Well, this court
is going to require Parkland Hospital to give aerosolized
Pentamidine," which actually is a fine drug, but was not approved
at the time for patients, "because we are not going to sit by and
6. Dallas Gay Alliance v. Dallas County Hosp. Dist., No. 88-6346-A ([ex.
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let these patients die." The truth is that patients are going to die,
and whether the court sits by or does not sit by is not the relevant
issue. This again is fantastical, magical thinking. It is a rescue
fantasy that we can save these people by giving them drugs that
do not work. The only way ultimately to rescue these people is to
develop drugs that do work, and the only way to do that is to
conduct randomized clinical trials.
Ms. Dunlap: I would like to offer a somewhat different view
in response to that question. It seems to me, in a way, that all of
our ideas are played out into a dichotomy, and I do not like to see
myself on the side on which I am finding myself which is in favor
of "scientific rationality."
I refer to the Village Voice, February 16, 1988. Women have
not been among the Ampligen subjects-Ampligen is a leading
AIDS-related drug that may be very important in prolonging life
among other things ...
Professor Annas: That is disputed.
Ms. Dunlap: ... but here is the reaction of Dr. Michael Greco
of St. Luke's Ampligen Program when accused of discriminating
against women: "Women are not part of five out of thirteen of
the trials going on right now. The best patients have been male
homosexuals. Woman," I think he means women, "have less
compliance. There is less education, motivation and understand-
ing. It is different taking someone who is productive in the arts
than living as a minority person. They are not going to have the
same grasp." Let me suggest that everything we wrap in the
wrappings of science may not be science. Everything we wrap in
the wrappings of politics may not be politics. It is extremely im-
portant for all of us to take a much closer look at people's under-
lying value systems when they are offering these models as
scientific or political or whatever they may be.
Professor Annas: Of course Dr. Greco's statement was a stu-
pid statement, if he made that statement.
Ms. Dunlap: Five drugs out of thirteen are not being tested
on women. Stupid or not, that is a scientific reality.
Professor Annas: The reality is and the reason they do not
test women is because they are afraid they are teratogens. There
are ways to get around that. You are correct, women are not be-
ing adequately tested, nor are intravenous drug users. I am not
sure that that is a deplorable thing necessarily. They are not get-
ting any kind of medical care. First, we want to get basic medical
992 [Vol. 34: p. 983
10
Villanova Law Review, Vol. 34, Iss. 5 [1989], Art. 8
https://digitalcommons.law.villanova.edu/vlr/vol34/iss5/8
1989] SYMPOSIUM PROCEEDINGS 993
care to everyone, then we can worry about experimentals medical
care.
Dr. Forrester: I would like to add as a health researcher that
I do subscribe to the scientific method and that I do support the
idea of the clinical trial. Yet, our patients are endlessly creative
and resourceful whether they are women or men. It is my experi-
ence that the scientific method goes out the window when our
patients go outside the clinic and trade their drugs. I don't worry
about them too much. Everyone is getting AZT. That is why
many of the AZT trials were abandoned; the patients were con-
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